Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir

Article summary

Enanta Pharmaceuticals has initiated its global Phase 2b/3 clinical trial, named RESOLVE, by dosing the first patient with zelicapavir for the treatment of RSV in high-risk adults.